Visual field testing: timing and analysis in patients with POAG

Article

The periodic assessment of vision function with visual field testing is a standard and important part of the management of primary open-angle glaucoma (POAG). Automated achromatic static threshold perimetry is the preferred technique, although other static and kinetic techniques are acceptable alternatives in patients who are unable to complete automated perimetry reliably or when the technology is not available.

The periodic assessment of vision function with visual field testing is a standard and important part of the management of primary open-angle glaucoma (POAG).1 Automated achromatic static threshold perimetry is the preferred technique,2-5 although other static and kinetic techniques are acceptable alternatives in patients who are unable to complete automated perimetry reliably or when the technology is not available.1

Determining an optimal interval between visual field testing in an individual patient with POAG can be challenging. Like most things in glaucoma, care must be individualized. In addition to considering clinical characteristics and patient risk factors in scheduling follow-up examinations, the physician must consider the data set required for using statistical tools to analyze visual field changes over time. This article explores clinical features and risk factors that should be considered in scheduling follow-up visits for visual field testing and the two primary analytical strategies-event analysis and trend analysis-in current use for quantifying visual field changes.

Recommended follow-up intervals

As shown in the table, the recommended follow-up interval varies from 1 to 12 months-a relatively wide range-depending on patient characteristics. A follow-up interval as short as 1 month may be indicated for patients who are just learning to take fields and whose tests are unreliable, for those in whom progression is suspected, to confirm progression, or for those in whom target IOP is not achieved. With new visual field software, it may be advisable to obtain a few fields in the first several months to establish a solid baseline. Other clinical settings also may require a short follow-up interval. No patients have a recommended follow-up interval longer than 12 months; thus, visual field and optic nerve head evaluation should be done at least annually under the best of circumstances. Of course, visual field testing may not provide for far advanced glaucoma when the field is nearly extinguished.1

In addition to automated achromatic threshold perimetry (AAP), several other visual field testing technologies are available. Visual field testing based on short-wavelength automated perimetry (SWAP) and frequency-doubling technology (FDT) may detect defects earlier than conventional white-on-white perimetry.6 To generate a useful measure of progression in an individual patient, the physician should employ a consistent testing strategy over time. It is not established whether SWAP or FDT will provide additional information about progression once AAP has demonstrated a glaucomatous defect.

The following factors should be considered when determining an appropriate follow-up interval for visual field testing and optic nerve evaluation1 :

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.